J&J said it is seeking a preliminary injunction for Samsung Bioepis' Stelara biosimilar over an unauthorized sublicense deal ...

The authors write "A recent court decision appears to be the first reported case that addresses an interesting question – ...

The Pitt is officially coming back for a second season Max declared on Valentines’ Day, and the legal fray between Michael ...

In a move that may clear the path for app stores to exert more control over deleting third-party apps, a California federal ...

The firm, which was involved in the Homewood Drive and Coulee Ile des Cannes projects, was fired by the Boulet administration ...

Takeaway: Former FBI Director Robert Mueller once famously said, “There are only two types of companies: those that have been hacked and those ...

In a recent article, I described the specific doctrinal, social, and informational dynamics that both render such contracts vulnerable to breach and frustrate their enforcement. This Article ...

Charleston Area Medical Center, which is part of Vandalia Health, is being sued due to a data breach that may have ...

"So four years later you're going to send me this letter?" LCS Superintendent Rocky Hanna said. "Come on, really?" ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

Johnson & Johnson (JNJ.N), opens new tab sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment.